Development of recombinant rsolCD39-PSGL as a novel therapeutic with anti-thrombotic and anti-inflammatory effects

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/520697

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Heart disease and stroke are due to a narrowing of arteries followed by occlusion, due a combination of clot formation initiated by platelet clumping, and inflammation surrounding the vessel wall. The currently available drugs are often limited by the adverse reaction of bleeding. We will investigate the efficiency of a new drug to prevent clot formation and inflammation.

Funded Activity Details

Start Date: 01-01-2008

End Date: 01-01-2009

Funding Scheme: NHMRC Development Grants

Funding Amount: $186,367.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Nutrigenomics and personalised nutrition

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

anti-inflammatory | antithrombotic | artery wall | cardiovascular disease | ischaemia/reperfusion injury | platelet aggregation | purine nucleotide biosynthesis | regulation of coagulation/blood clotting

Related Links